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1142-183 Association of Prehypertension by Joint National 
Committee 7 Criteria With Left Ventricular Structure and 
Function: The Strong Heart Study
Marilyn B. Lawrence Wright, Richard B. Devereux, Mary J. Roman, Marcello Chinali, Lyle 
G. Best, James Galloway, Richard R. Fabsitz, Elisa T. Lee, Ying Zhang, Barbara V. 
Howard, Weill Medical College of Cornell University, New York, NY
Background: Hypertension (HTN) and left ventricular (LV) structure and function predict
cardiovascular events. The JNC 7 prehypertension (preHTN) category lowers the blood
pressure (BP) level at which cardiovascular risk for the general population is considered
significant. Methods: Using JNC 7 criteria to define BP groups, we compared clinical
features and LV structure and function in 776 normal BP (nlBP), 859 preHTN, 1,074
stage 1 HTN and 379 stage 2 HTN Strong Heart Study participants. Results: Partici-
pants were mostly female (63%), mean age 60 ± 8 years. Compared to the nlBP group,
preHTN and HTN participants were older, more obese, more likely to have diabetes and
less likely to smoke (all p < 0.01), with no difference in gender distribution, mean LDL or
HDL cholesterol. Plasma creatinine was higher with HTN and urine albumin/creatinine
ratio higher with preHTN and HTN (both p < 0.05). After adjusting for differences among
groups in age, diabetes, body mass index, smoking, study center and plasma creatinine,
LV mass and geometry were significantly different with preHTN and HTN compared to
nlBP. Compared to nlBP participants, LV systolic and diastolic function was significantly
different in HTN but not preHTN participants. (Table 1) Conclusion: PreHTN is associ-
ated with significant abnormalities of LV geometry and an increased prevalence of LV
hypertrophy. It is not associated with significant LV systolic or diastolic dysfunction. Fur-
ther research on clinical cardiovascular risk in preHTN is needed. 
1142-184 Contribution of Apolipoprotein A5 Gene Variants to Left 
Ventricle Hypertrophy in Hypertensive African-
American Men
Deborah Lyn, Rigobert Lapu-Bula, Cheryl Pack, Jason Nguyen, Jan Morgan, Elizabeth 
Ofili, Morehouse School of Medicine, Atlanta, GA
Background: Left ventricle mass (LVM) has been associated with metabolic measures
such as triglyceride levles in hypertensives (HTN). Variations in triglyceride levels have
been linked with polymorphisms in the apolipoprotein A5 (ApoA5) gene. It has not been
ascertained whether changes in cardiac structure are linked to APOA5 gene variants
related to hypertensive LV hypertrophy (LVH). Methods: The —1131T>C and 56C>G
(S19W) variants of the ApoA5 gene were determined in 92 normotensive and 123 HTN
African Americans without hyperlipedemia, diabetes or prior cardiac event. Echocardio-
grahic LVM was assessed to define LVH (>134/110 g/m2 men/women). Results: HTN
men bearing the —1131C and 56C alleles (C:C haplotype) had a significantly higher LVM
index compared to those with (T:C) haplotype. This association existed after multivariant
analysis when adjusted for body mass index. No significant differences in LVM were seen
in HTN women or normotensives related to these variants. Consistent with other studies,
the frequency of the 56G variant was linked to higher fasting triglyceride (p=0.05) and
lower HDL cholesterol (p=0.03) levels only in HTNs. Conclusion: These data suggest an
increased susceptibility to LVH in HTN men who carry the —1131C variant in the pro-
moter region. This study raises the possibility that apoA5 levels may play a role in lipid
transport in the development of cardiac hypertrophy.
LVM Index by Haplotypes in HTN 
Mean± SD g/m2 indexed to body surface area (n). Men p<0.01 Women p=0.84, T:C vs
C:C
1142-185 Cardiac Structural and Functional Responses to Salt 
Loading in Spontaneously Hypertensive Rats
Jwari Ahn, Jasmina Varagic, Dinko Susic, Michel Slama, Edward D. Frohlich, Ochsner 
Clinic Foundation, New Orleans, LA
Background: Increased dietary salt intake induces cardiac fibrosis in the spontaneously
hypertensive rat (SHR), yet little information details its effects on LV function. In addition,
young rats seem to be more susceptible to salt excess than older.
Methods: SHR at 8 or 20 weeks of age were given 8% salt diet; age-matched controls
received standard rat chow. Echocardiographic indices, arterial pressure and LV hydrox-
yproline concentration were measured at 16 and 52 weeks in the young and aged adult
SHR groups, respectively.
Results: In most SHR, given salt excess increased arterial pressure, LV mass and
hydroxyproline concentration associated with impaired LV relaxation manifested by pro-
longed isovolumic relaxation time, decreased early (E) and atrial filling (A) velocity ratio
(E/A) and slower propagation velocity of early filling (Vp). LV systolic function remained
normal. One-fourth of the young adult salt-loaded SHR developed cardiac failure associ-
ated with systolic and diastolic dysfunction with greater LV mass and fibrosis. These rats
had lower arterial pressure, decreased fractional shortening and restrictive pattern of
mitral flow. Shorter deceleration time of E wave and increased E/Vp ratio, an index of LV
filling pressure, indicated increased LV stiffness.
Conclusions: Increased sodium sensitivity in SHR not only is manifested by further eleva-
tion of blood pressure, but significant cardiac dysfunction, most likely related to ventricu-
lar fibrosis, also occurs, especially in the young.
1142-186 Elevated Levels of Circulating Tissue Inhibitor of 
Metalloproteinase-1 Correlate With Impaired Diastolic 
Relaxation in Hypertension: Implications for Diastolic 
Heart Failure
Muzahir H. Tayebjee, Sunil K. Nadar, Robert J. Macfadyen, Gregory YH Lip, City 
Hospital, Birmingham, United Kingdom
Background
Hypertension(HT), hypertensive heart disease and left ventricular (LV) hypertrophy are
integral to symptomatic diastolic heart failure. Tissue inhibitor of metalloproteinase 1
(TIMP-1) is linked to extracellular matrix fibrosis and is elevated in HBP. We explored the
link between circulating TIMP-1, matrix metalloproteinase 9 (MMP-9) and resting
echocardiographic LV filling.
Methods: Circulating MMP-9 and TIMP-1 levels were measured in citrated plasma by
ELISA in 52 patients with HT (38 male, age 57 + 11yrs) and 24 controls (15 male, mean
age 53+ 12years). Demography and standard resting echocardiographic indices of dias-
Table 1
Normotension Prehypertension Hypertension
SBP(mmHg) 109.0 ± 0.8 127.7± 0.4 150.2±0.9**
DBP (mmHg) 73.2±0.7 84.0±2.9* 89.6±0.8**
LVEDD (mm) 46.8±0.6 48.5±0.5* 49.8± 0.4*
LVM (g) 134.1±4.0 156.2±3.2* 178.9±5.9**
BNP (pg/ml) 22.0±2.2 21.8±2.3 30.7±3.2*
Table 1. LV Structure and Function in Study Participants grouped by BP Category
Variable NlBP
(N = 776)
PreHTN
(N = 859)
Stage 1 HTN
(N = 1074)
Stage 2 HTN
(N = 379)
LV end-diastolic diameter 
(cm)
4.89 ± 0.43 4.95 ± 
0.479 
5.03 ± 0.547 
β
5.12 ± 0.582 
β
Relative wall thickness 0.34 ± 
0.044
0.35 ± 
0.045*
0.35 ± 
0.049*
0.36 ± 
0.061_
LV Mass/height2.7 (g/m2.7) 37.5 ± 7.96 40.6 ± 8.84β 44.0 ± 11.06 
β
48.3 ± 13.32 
β
Eccentric LV Hypertrophy 
(%)
10.6 18.9 29.1 β 42.3 β
Concentric LV Hypertrophy 
(%)
1.0 2.1 3.2 6.1*
Ejection fraction (%) 64 ± 7.1 64 ± 7.7 62 ± 9.9 _ 61 ± 11.4 β
E/A ratio 0.92 ± 
0.291
0.86 ± 
0.249
0.82 ± 
0.348*
0.80 ± 0.369
Statistical significance versus nlBP: * = p < 0.05,  α = p < 0.01,  β = p < 0.001
T:C C:C T:G C:G
Male 112± 31 (39) 141± 44 (14) (0) (0)
Female 99± 27 (41) 101± 28 (17) 104± 30 (7) 72 (1)
Arterial Pressure and Echocardiographic Indices
ADULT
CONTROL
ADULT 
SALT
without CF
ADULT SALT
with CF
AGED
CONTROL
AGED
SALT
Arterial 
Pressure
(mmHg)
206 ± 9 243 ± 8* 164 ± 18*† 207 ± 6 242 ± 78*
LV Mass (g) 0.86 ± 0.04 1.12 ± 0.04* 1.39 ± 0.07*† 1.31± 0.03 1.53 ± 
0.06*
Left End 
Diastolic
Diameter (cm)
0.73 ± 0.02 0.75 ± 0.01 0.85 ± 0.02*† 0.84 ± 0.01 0.87± 0.02
Fractional
Shortening (%)
41 ± 1 44 ± 1 35 ± 1*† 41.2 ± 1 44.3± 1
E/A 2.56 ± 0.12 1.50 ± 0.12* 2.54 ± 0.20† 2.58 ± 0.21 2.18± 0.15
Deceleration 
Time
of E Wave (sec)
0.045 ± 
0.001
0.040 ± 
0.002*
0.036 ± 
0.002*
0.046 ± 
0.002
0.042 ± 
0.002
Vp (cm/s) 28.5 ± 0.76 25.1 ± 0.56* 24.9 ± 1.22* 24.7 ± 0.65 24.6 ± 0.63
E/Vp 0.028 ± 
0.001
0.031 ± 
0.001
0.039 ± 
0.002*†
0.032 ± 
0.001
0.034 ± 
0.001
LV 
Hydroxyproline
(mg/g)
4.57 ± 0.17 5.75 ± 0.12* 6.84 ± 0.57*† 4.85 ± 0.24 6.02 ± 
0.49*
*p<0.05 vs Respective Control, †p<0.05 vs Adult Salt without CF
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tolic function were recorded.All had confirmed normal short axis systolic contractility.
Diastolic function was studied by means of tissue doppler.
Results: Echocardiographic indices were predictably abnormal, and plasma MMP-9 &
TIMP-1 were elevated in HT. Within the hypertensive cohort, LV mass and septal thick-
ness correlated positively with TIMP-1 (Ranked Pearson’s correlation r=0.312,p=0.035;
r=0.359,p=0.013 respectively). There was a negative correlation between e’ and TIMP-1
(r= -0.296,p=0.037).
Conclusion: We have defined a novel relationship between elevated TIMP-1, increased
LV mass and impaired diastolic relaxation. This suggests a role for this metalloproteinase
inhibitor in the patho-physiology of hypertensive heart disease potentially related to dias-
tolic heart failure in HT.
1142-187 Three-Dimensional Echocardiographic and Magnetic 
Resonance Assessment of the Effect of Telmisartan 
Compared With Carvedilol on Left Ventricular Mass: A 
Multicenter, Randomized, Controlled Study
Domenico Galzerano, Luca Del Viscovo, Paolo Tammaro, Carlo Tedeschi, Roberto 
Breglio, Diana Lama, Antonio Cerciello, Bernardino Tuccillo, Paolo Capogrosso, San 
Gennaro Hospital, Naples, Italy
Background: Meta-analyses examining hypertensive left ventricular hypertrophy (LVH)
suggest that the observed regression of LVH is related not only to blood pressure control,
but also to drug-related effects.
Objective: To elucidate the efficacy and the effects on left ventricular mass of different
classes of drugs, on the hypothesis that blockade of angiotensin II type 1 (AT1) receptors
by the AT1 receptor antagonist telmisartan (TEL) would reduce left ventricular mass
assessed by three-dimensional echocardiography (3DE) and magnetic resonance imag-
ing (MRI) more than conventional treatment with the beta-blocker carvedilol (CARV).
Design and Methods: This study randomized 80 patients with mild-to-moderate hyperten-
sion plus LVH and optimal acoustic window to receive either TEL 80 mg od or CARV 25
mg od for 40 weeks. Ten patients withdrew from the study because diastolic blood pres-
sure remained above 90 mmHg. At baseline and after the 40-week treatment, blood
tests, 3DE and 24-h ABPM were performed. 28 patients underwent MRI.
RESULTS: Systolic and diastolic blood pressure reductions were similar in both treat-
ment groups(before and after TEL: 160±9.5and 97.8±5.8 vs 128±6.5/77.3±5.4 mmHg;
CARV: 160±10.7 and 95.4±4.9 vs 128.4±4.9 and 78.3±4.8 mmHg). Both TEL (P<0.001)
and CARV (P<0.01) progressively reduced left ventricular mass index by 22 and 12 g/m2
(15% and 9%), respectively, at week 40 (P=0.02). A higher percentage of normalized left
ventricular mass was achieved in the TEL group (44% vs 30%).
CONCLUSIONS: TEL produced a greater reduction of left ventricular mass than CARV,
suggesting that AT1 receptor blockade provides an important mechanism, beyond that of
lowering blood pressure, in the regression of left ventricular mass in hypertensive
patients.
1142-188 Pulse Wave Velocity Measured by Complior Method in a 
Brazilian Young Population Followed-Up for a 13 Year-
Period: The Rio de Janeiro Study
Oswaldo Pizzi, Roberto Pozzan, Andréa Brandão, Maria Eliane Magalhães, Elizabete 
Freitas, Ayrton Brandão, State University of Rio de Janeiro, Rio de Janeiro, Brazil, 
Medical School of Petrópolis, Petrópolis, Brazil
Background: Vascular injury in youth associated to early blood pressure (BP) alterations
and other risk factors is not well known. To establish their possible association, pulse
wave velocity (PWV), clinical, metabolic and haemodynamic variables were measured in
young adults stratified by their blood pressure percentile obtained 13 years earlier.
Methods: 385 young subjects (201M) were evaluated at their schools in 1987-88
(12.74±1.65 y). BP was measured 3 times, and the third measure was used for analysis.
Body mass index (BMI) was obtained. In 1997-2000 (21,91±2,12 y), they were examined
at the hospital. BP, BMI, waist and hip were obtained and cholesterol (C), tryglicerides,
LDL-C, HDL-C, creatinine, plasma glucose and insulin were measured after a 12h fast-
ing. A sample of 60 young adults underwent PWV measurement by Complior method
and was stratified according to their former (at school) BP percentile: Group 1 < 50th per-
centile (n=25, 11 M) and Group 2 > 95th percentile (n=35, 19 M).
Results: 1) Group 1 had higher age (p<.05) and all comparisons were adjusted for age.
2) Group 2 had higher weight (p<.05), systolic BP (SBP) (p<.03), diastolic BP (DBP)
(p<.02), mean BP (MBP) (p<.02), PWV (p<.03), fasting glucose (p<.03) and lower HDL-C
(p<.03). 3) PWV correlated positively and significantly with SBP (r=0.333, p<.02), MBP
(r=0.303, p<.02) and heart rate (HR) (r=0.284, p<.03) obtained 13 years earlier. 4) PWV
showed significant correlations with the following current variables: weight (r=0.403,
p<.01), height (r=0.301, p<.02), waist circumference (r=0.347, p<0.01), waist/hip ratio
(r=0.328, p=0.01), SBP (r=0.444, p<.01), DBP (r=0.318, p<.02), pulse pressure (PP)
(r=0.274, p<.04), MBP (r=0.424, p<.01) and serum creatinin (r=0.400, p<.01). 5) In co-
variance analysis, when PWV was adjusted for current SBP, DBP, MBP and PP, no signif-
icant differences were observed between the groups, although group 2 showed higher
means in all comparisons.
Conclusion: High BP percentile obtained in adolescence was associated with higher BP
and PWV 13 years later. These results suggest that early vascular changes could be
identified in young and emphasize that primary prevention must begin early in life.
ORAL CONTRIBUTIONS
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847-1 Constellation of Risk Variables of Metabolic Syndrome 
at Low Levels in Childhood Is Beneficially Associated 
With Adulthood Cardiovascular Risk: The Bogalusa 
Heart Study
Wei Chen, Sathanur R. Srinivasan, Shengxu Li, Jihua Xu, Gerald S. Berenson, Tulane 
University Health Sciences Center, New Orleans, LA
Background: Most epidemiologic studies have focused on the association between the
adverse levels of risk variables of metabolic syndrome and the risk of cardiovascular (CV)
disease. However, information is lacking on the relation of metabolic syndrome risk vari-
ables clustering at favorable levels in childhood and CV disease risk in adulthood.
Methods: The study cohort (n=1,474) was examined in childhood (4-17 years) and again
in adulthood (18-41 years), with an average follow-up period of 15.8 years in a black-
white community. The childhood criterion metabolic syndrome variables included the low-
est quartiles (specific for age, race, sex and study year) of body mass index, homeostasis
model assessment of insulin resistance, systolic blood pressure and total cholesterol/
high-density lipoprotein cholesterol ratio. The measures of CV risk in adulthood included
prevalence of metabolic syndrome, parental histories of CV disease, and carotid artery
intima-media thickness (IMT) measured in a subsample (n=138).
Results: In childhood, 9% of the cohort displayed clustering of 3 or 4 criterion risk vari-
ables at the bottom quartiles, which was significantly higher than expected by chance
alone (P<0.01). These children, compared with those without any risk variables at the
bottom quartiles, had a lower prevalence of metabolic syndrome in adulthood (2.3% vs
20.0%, P<0.001). In addition to lower odds for having metabolic syndrome in adulthood
(11-fold, P<0.001), they also displayed lower odds for having parental histories of CHD
(1.9-fold, P=0.039), hypertension (1.5-fold, P=0.045 ) and type 2 diabetes (1.6-fold,
P=0.079). Mean values of carotid IMT in adulthood decreased with an increasing number
of risk variables clustering at the bottom quartiles in childhood (P for trend=0.013).
Conclusion: The constellation of metabolic syndrome variables at low levels in child-
hood is associated with lower measures of CV risk in adulthood. The beneficial conse-
quence of such a lifetime low-risk profile in youth reinforces the importance of CV
disease health promotion and life style modification in early life.
2:15 p.m.
847-2 Combination Aspirin and Statin Therapy Markedly 
Reduces C-Reactive Protein Levels in a High-Risk 
Population Without Coronary Disease
Marlene S. Williams, Lewis C. Becker, Taryn F. Moy, Lisa R. Yanek, Nauder Faraday, 
Diane M. Becker, Johns Hopkins Medical Institution, Baltimore, MD
Background: There remains controversy about the anti-inflammatory effects of both low
dose aspirin (ASA) (81mg) therapy and statins and little is known of their combined
effect. This study was designed to determine the extent to which chronic low dose ASA
therapy, statin therapy, and combined statin and ASA therapy have an anti-inflammatory
effect as determined by plasma levels of high sensitivity C-reactive protein (hs-CRP) in a
high-risk population without coronary artery disease (CAD). Methods: We examined 699
asymptomatic siblings (SIBS) of probands with documented CAD < 60 years of age.
SIBS were 49.0 ± 8 years of age, 59% African American, and 41% male and were not
using regular nonsteroidal or other anti-inflammatory agents. Plasma levels of hs-CRP
were measured by ELISA. Three separate multivariate regression models were used,
one each for the use of ASA alone, statins alone, and combination therapy, each control-
ling for age, sex, race, systolic blood pressure, LDL-cholesterol, smoking, diabetes, and
body mass index. Each model contained only people using the specific therapy of inter-
est, plus nonusers. Results: Lower levels of hs-CRP were observed in individuals using
ASA alone (N=23) hs-CRP= 2.1± 1.8 µg/ml, statins alone(N=56) hs-CRP=2.8± 2.6 µg/ml,
and the combination of both statins and ASA(N=13) hs-CRP=1.4± 1.4 µg/ml, in compari-
son with nonusers (N=607) hs-CRP=3.1± 3.0 µg/ml. Combined therapy was the stron-
gest independent predictor of lower hs-CRP levels (p=0.0008). For people using statins
alone, the multivariate adjusted significance was lower, (p=0.007), and for people using
Differences between controls and hypertensives
Controls (n=24) Hypertensives (n=52) p-value
SBP 127(16) 154(22) <0.0001
DBP 79(10) 90(13) <0.001
Cholesterol (mmol/l) 5.7 (5.1-6.1) 5.2 (4.8-6.1) 0.33
LV mass (gm) 182 (68) 231 (85) 0.009
IVRT (msec) 110(99-130) 122(106-143 0.39
E-wave(cm/sec) 0.73(0.15) 0.81(0.02) 0.03
A-wave (cm/sec) 0.67(0.03) 0.83(0.02) <0.001
e' wave(cm/sec) 0.1(0.078-0.12) 0.08(0.07-0.1) 0.009
e'/a' 7.4(2.2) 9.2(2.5) 0.002
MMP-9 42(35-103) 70(45-135) 0.029
TIMP-1 290(230-350) 380(273-580) 0.005
